|
|
Blood, 1 January 2004, Vol. 103, No. 1, pp. 275-282.
Prepublished online as a Blood First Edition Paper on September 22, 2003; DOI 10.1182/blood-2003-05-1545.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,
Dennis D. Weisenburger,
Timothy C. Greiner,
Randy D. Gascoyne,
Jan Delabie,
German Ott,
H. Konrad Müller-Hermelink,
Elias Campo,
Rita M. Braziel,
Elaine S. Jaffe,
Zenggang Pan,
Pedro Farinha,
Lynette M. Smith,
Brunangelo Falini,
Alison H. Banham,
Andreas Rosenwald,
Louis M. Staudt,
Joseph M. Connors,
James O. Armitage, and
Wing C. Chan
From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha; Departments of Pathology and Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; Department of Pathology, Norwegian Radium Hospital, Oslo, Norway; Department of Pathology, University of Würzburg, Germany; Department of Pathology, Hospital Clinic, University of Barcelona, Spain; Southwest Oncology Group and Department of Pathology, University of Oregon Health Sciences Center, Portland; Hematopathology Section and Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Institute of Hematology, University of Perugia, Italy; and Department of Clinical Laboratory Sciences, University of Oxford, United Kingdom.
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-celllike (GCB), activated B-celllike (ABC), and type 3 gene expression profiles using a cDNA microarray. Tissue microarray (TMA) blocks were created from 152 cases of DLBCL, 142 of which had been successfully evaluated by cDNA microarray (75 GCB, 41 ABC, and 26 type 3). Sections were stained with antibodies to CD10, bcl-6, MUM1, FOXP1, cyclin D2, and bcl-2. Expression of bcl-6 (P < .001) or CD10 (P = .019) was associated with better overall survival (OS), whereas expression of MUM1 (P = .009) or cyclin D2 (P < .001) was associated with worse OS. Cases were subclassified using CD10, bcl-6, and MUM1 expression, and 64 cases (42%) were considered GCB and 88 cases (58%) non-GCB. The 5-year OS for the GCB group was 76% compared with only 34% for the non-GCB group (P < .001), which is similar to that reported using the cDNA microarray. Bcl-2 and cyclin D2 were adverse predictors in the non-GCB group. In multivariate analysis, a high International Prognostic Index score (3-5) and the non-GCB phenotype were independent adverse predictors (P < .0001). In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Copie-Bergman, P. Gaulard, K. Leroy, J. Briere, M. Baia, J.-P. Jais, G. A. Salles, F. Berger, C. Haioun, H. Tilly, et al.
Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
J. Clin. Oncol.,
November 20, 2009;
27(33):
5573 - 5579.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Seki, K. Ohshima, T. Fujisaki, N. Uike, F. Kawano, H. Gondo, S. Makino, T. Eto, Y. Moriuchi, F. Taguchi, et al.
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab
Ann. Onc.,
November 4, 2009;
(2009)
mdp481v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-K. Song, J.-S. Chung, Y.-M. Seol, S.-G. Kim, H.-J. Shin, Y.-J. Choi, G.-J. Cho, and D.-H. Shin
Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy
Ann. Onc.,
November 3, 2009;
(2009)
mdp505v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ennishi, H. Asai, Y. Maeda, K. Shinagawa, K. Ikeda, M. Yokoyama, Y. Terui, K. Takeuchi, T. Yoshino, K. Matsuo, et al.
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Ann. Onc.,
November 2, 2009;
(2009)
mdp490v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-W. Bernd, M. Ziepert, C. Thorns, W. Klapper, H.-H. Wacker, M. Hummel, H. Stein, M.-L. Hansmann, G. Ott, A. Rosenwald, et al.
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
Haematologica,
November 1, 2009;
94(11):
1569 - 1580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Savage, N. A. Johnson, S. Ben-Neriah, J. M. Connors, L. H. Sehn, P. Farinha, D. E. Horsman, and R. D. Gascoyne
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
Blood,
October 22, 2009;
114(17):
3533 - 3537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chadburn, A. Chiu, J. Y. Lee, X. Chen, E. Hyjek, A. H. Banham, A. Noy, L. D. Kaplan, J. A. Sparano, K. Bhatia, et al.
Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034
J. Clin. Oncol.,
October 20, 2009;
27(30):
5039 - 5048.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E C Obermann, M Csato, S Dirnhofer, and A Tzankov
BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma
J. Clin. Pathol.,
October 1, 2009;
62(10):
903 - 907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F H Heyning, P C W Hogendoorn, M H H Kramer, C T Q Holland, E Dreef, and P M Jansen
Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype
J. Clin. Pathol.,
September 1, 2009;
62(9):
820 - 824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. W.L. Choi, D. D. Weisenburger, T. C. Greiner, M. A. Piris, A. H. Banham, J. Delabie, R. M. Braziel, H. Geng, J. Iqbal, G. Lenz, et al.
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
Clin. Cancer Res.,
September 1, 2009;
15(17):
5494 - 5502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Aster and J. Kutok
Complexity Made Simple in Diffuse Large B-Cell Lymphoma
Clin. Cancer Res.,
September 1, 2009;
15(17):
5291 - 5293.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Uccella, R Cerutti, C Placidi, S Marchet, I Carnevali, B Bernasconi, I Proserpio, G Pinotti, M G Tibiletti, D Furlan, et al.
MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression
J. Clin. Pathol.,
August 1, 2009;
62(8):
715 - 723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Tomita, M. Tokunaka, N. Nakamura, K. Takeuchi, J. Koike, S. Motomura, K. Miyamoto, A. Kikuchi, R. Hyo, Y. Yakushijin, et al.
Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations
Haematologica,
July 1, 2009;
94(7):
935 - 943.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Nagel, T. Akasaka, W. Klapper, S. Gesk, S. Bottcher, M. Ritgen, L. Harder, M. Kneba, M. J.S. Dyer, and R. Siebert
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma
Haematologica,
July 1, 2009;
94(7):
1020 - 1023.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Rossi, V. Spina, M. Cerri, S. Rasi, C. Deambrogi, L. De Paoli, L. Laurenti, R. Maffei, F. Forconi, F. Bertoni, et al.
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
Clin. Cancer Res.,
July 1, 2009;
15(13):
4415 - 4422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Cha, S. J. Noh, K. S. Kwon, C. Y. Kim, B.-H. Park, H. S. Park, H. Lee, M. J. Chung, M. J. Kang, D. G. Lee, et al.
Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma
Clin. Cancer Res.,
July 1, 2009;
15(13):
4453 - 4459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Tam
Micro-classifying diffuse large B-cell lymphomas
Blood,
June 25, 2009;
113(26):
6506 - 6507.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Li, S.-W. Kim, D. Rai, A. R. Bolla, S. Adhvaryu, M. C. Kinney, R. S. Robetorye, and R. C. T. Aguiar
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma
Blood,
June 25, 2009;
113(26):
6681 - 6690.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright, N. Grant, M. Shovlin, E. S. Jaffe, J. E. Janik, L. M. Staudt, et al.
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Blood,
June 11, 2009;
113(24):
6069 - 6076.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Balague, A. Mozos, D. Martinez, L. Hernandez, L. Colomo, J. L. Mate, J. Teruya-Feldstein, O. Lin, E. Campo, A. Lopez-Guillermo, et al.
Activation of the Endoplasmic Reticulum Stress-Associated Transcription Factor X Box-Binding Protein-1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive B-Cell Lymphomas with Prognostic Implications
Am. J. Pathol.,
June 1, 2009;
174(6):
2337 - 2346.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zhang, D. D. Jima, C. Jacobs, R. Fischer, E. Gottwein, G. Huang, P. L. Lugar, A. S. Lagoo, D. A. Rizzieri, D. R. Friedman, et al.
Patterns of microRNA expression characterize stages of human B-cell differentiation
Blood,
May 7, 2009;
113(19):
4586 - 4594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Johnson, M. Boyle, A. Bashashati, S. Leach, A. Brooks-Wilson, L. H. Sehn, M. Chhanabhai, R. R. Brinkman, J. M. Connors, A. P. Weng, et al.
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Blood,
April 16, 2009;
113(16):
3773 - 3780.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Malumbres, K. A. Sarosiek, E. Cubedo, J. W. Ruiz, X. Jiang, R. D. Gascoyne, R. Tibshirani, and I. S. Lossos
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas
Blood,
April 16, 2009;
113(16):
3754 - 3764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Maeshima, H. Taniguchi, J. Nomoto, D. Maruyama, S.-W. Kim, T. Watanabe, Y. Kobayashi, K. Tobinai, and Y. Matsuno
Secondary CD5+ Diffuse Large B-Cell Lymphoma Not Associated With Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Richter Syndrome)
Am J Clin Pathol,
March 1, 2009;
131(3):
339 - 346.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ennishi, M. Yokoyama, Y. Terui, H. Asai, S. Sakajiri, Y. Mishima, S. Takahashi, H. Komatsu, K. Ikeda, K. Takeuchi, et al.
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
Ann. Onc.,
March 1, 2009;
20(3):
526 - 533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. V. Lee, C. A. Green, O. G. Negrea, S. Dodson, S. K. Farrell, J. E. Hewitt, T. Jago, C. E. Ramsey, T. Cato, E. Crawford, et al.
B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP
Lab Med,
February 1, 2009;
40(2):
79 - 86.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D de Jong, W Xie, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, B Sander, C Thorns, E Campo, et al.
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)
J. Clin. Pathol.,
February 1, 2009;
62(2):
128 - 138.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A E Hallack Neto, S A C Siqueira, F L Dulley, M A Ruiz, D A F Chamone, and J Pereira
p63 Protein expression in high risk diffuse large B-cell lymphoma
J. Clin. Pathol.,
January 1, 2009;
62(1):
77 - 79.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Smith, B. Bolwell, A. Advani, S. Andresen, J. Chan, R. Dean, E. Hsi, M. Kalaycio, B. Pohlman, L. Rybicki, et al.
High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
1137 - 1137.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
G. Gutierrez-Garcia, L. Colomo, N. Villamor, L. Arenillas, A. Martinez, M. Camos, M. Diaz-Beya, C. F. de Larrea, X. Calvo, E. Gine, et al.
No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
3615 - 3615.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
D. J Andorsky, R. Yamada, K. K Steward, S. De Vos, J. Said, and J. M Timmerman
Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkin's Lymphomas
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
4140 - 4140.
[Abstract]
|
 |
|

|
 |

|
 |
 
S.-a. Lee, H.-M. Ryoo, S. H. Bae, H. Y. Jung, S. B. Jang, and Y. S. Keum
The Predictive Role of Germinal Center or Non-Germinal Center Phenotypes in Diffuse Large B-Cell Lymphoma Patients Receiving CHOP or R-CHOP
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
5290 - 5290.
[Abstract]
|
 |
|

|
 |

|
 |
 
H. D. Brooks, R. M. Graham, R. L. Woodford, A. K. Bennett, X. Q. Wang, M. E. Williams, and J. B. Cousar
LMO2 and Bcl-6 Expression in Diffuse Large B-Cell Lymphoma Predict Overall Survival in R-CHOP Treated Patients
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
5304 - 5304.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. H. Coles, C. G.A. Marfella, A. N. Imbalzano, H. A. Steinman, D. S. Garlick, R. M. Gerstein, and S. N. Jones
p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis
Cancer Res.,
November 1, 2008;
68(21):
8705 - 8714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, et al.
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Ann. Onc.,
November 1, 2008;
19(11):
1921 - 1926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. H. Young, K. Leroy, M. B. Moller, G. W. B. Colleoni, M. Sanchez-Beato, F. R. Kerbauy, C. Haioun, J. C. Eickhoff, A. H. Young, P. Gaulard, et al.
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
Blood,
October 15, 2008;
112(8):
3088 - 3098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al.
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
October 1, 2008;
26(28):
4587 - 4594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi
Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas
Ann. Onc.,
October 1, 2008;
19(10):
1774 - 1786.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, et al.
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Blood,
September 15, 2008;
112(6):
2248 - 2260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yamaguchi, N. Nakamura, R. Suzuki, Y. Kagami, M. Okamoto, R. Ichinohasama, T. Yoshino, J. Suzumiya, T. Murase, I. Miura, et al.
De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients
Haematologica,
August 1, 2008;
93(8):
1195 - 1202.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Malumbres, J. Chen, R. Tibshirani, N. A. Johnson, L. H. Sehn, Y. Natkunam, J. Briones, R. Advani, J. M. Connors, G. E. Byrne, et al.
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Blood,
June 15, 2008;
111(12):
5509 - 5514.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Krajewska, S. Kitada, J. N. Winter, D. Variakojis, A. Lichtenstein, D. Zhai, M. Cuddy, X. Huang, F. Luciano, C. H. Baker, et al.
Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies
Clin. Cancer Res.,
May 15, 2008;
14(10):
3011 - 3021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nakamura, H. Ye, C. M. Bacon, A. Goatly, H. Liu, L. Kerr, A. H. Banham, B. Streubel, T. Yao, M. Tsuneyoshi, et al.
Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma
Clin. Cancer Res.,
May 15, 2008;
14(10):
3002 - 3010.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. E. Craig and K. A. Foon
Flow cytometric immunophenotyping for hematologic neoplasms
Blood,
April 15, 2008;
111(8):
3941 - 3967.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kojima, N. Nakamura, K. Shimizu, Y. Tamaki, H. Itoh, and S. Nakamura
Marginal Zone B-Cell Lymphoma Among Primary B-Cell Lymphoma of Waldeyer's Ring: Histopathologic and Immunohistochemical Study of 16 Tonsillectomy Specimens
International Journal of Surgical Pathology,
April 1, 2008;
16(2):
164 - 170.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Jacob, M. Jentsch, D. Kostka, S. Bentink, and R. Spang
Detecting hierarchical structure in molecular characteristics of disease using transitive approximations of directed graphs
Bioinformatics,
April 1, 2008;
24(7):
995 - 1001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Jardin, P. Ruminy, J.-P. Kerckaert, F. Parmentier, J.-M. Picquenot, S. Quief, C. Villenet, G. Buchonnet, M. Tosi, T. Frebourg, et al.
Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas
Haematologica,
April 1, 2008;
93(4):
543 - 550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Ann. Onc.,
March 1, 2008;
19(3):
560 - 565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Brown, S. L. Ashe, E. Leich, C. Burek, S. Barrans, J. A. Fenton, A. S. Jack, K. Pulford, A. Rosenwald, and A. H. Banham
Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL
Blood,
March 1, 2008;
111(5):
2816 - 2824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tzankov, C. Meier, P. Hirschmann, P. Went, S. A. Pileri, and S. Dirnhofer
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
Haematologica,
February 1, 2008;
93(2):
193 - 200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Ding, J. J. Yu, R. Y.-L. Yu, L. M. Mendez, R. Shaknovich, Y. Zhang, G. Cattoretti, and B. H. Ye
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
Blood,
February 1, 2008;
111(3):
1515 - 1523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Natkunam, P. Farinha, E. D. Hsi, C. P. Hans, R. Tibshirani, L. H. Sehn, J. M. Connors, D. Gratzinger, M. Rosado, S. Zhao, et al.
LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
J. Clin. Oncol.,
January 20, 2008;
26(3):
447 - 454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Montes-Moreno, G. Roncador, L. Maestre, N. Martinez, L. Sanchez-Verde, F. I. Camacho, J. Cannata, J. L. Martinez-Torrecuadrada, Y. Shen, W. C. Chan, et al.
Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas
Blood,
January 1, 2008;
111(1):
351 - 358.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. G. M. Cillessen, J. C. Reed, K. Welsh, C. Pinilla, R. Houghten, E. Hooijberg, J. Deurhof, K. C. M. Castricum, P. Kortman, C. J. Hess, et al.
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells
Blood,
January 1, 2008;
111(1):
369 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K L Grogg, R F Miller, and A Dogan
HIV infection and lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1365 - 1372.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A.G.M. Cillessen, C. J. Hess, E. Hooijberg, K. C.M. Castricum, P. Kortman, F. Denkers, W. Vos, M. A. van de Wiel, G. J. Schuurhuis, G. J. Ossenkoppele, et al.
Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma
Clin. Cancer Res.,
December 1, 2007;
13(23):
7012 - 7021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B Lofstrom, C Backlin, C Sundstrom, A Ekbom, and I E Lundberg
A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study
Ann Rheum Dis,
December 1, 2007;
66(12):
1627 - 1632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Ramos-Vara, M. A. Miller, and V. E. O. Valli
Immunohistochemical Detection of Multiple Myeloma 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Plasmacytoma: Comparison with CD79a and CD20
Vet. Pathol.,
November 1, 2007;
44(6):
875 - 884.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Lin and L. J. Medeiros
High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis
Haematologica,
October 1, 2007;
92(10):
1297 - 1301.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Le Gouill, P. Talmant, C. Touzeau, A. Moreau, R. Garand, N. Juge-Morineau, F. Gaillard, T. Gastinne, N. Milpied, P. Moreau, et al.
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement
Haematologica,
October 1, 2007;
92(10):
1335 - 1342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Valsami, V. Pappa, D. Rontogianni, F. Kontsioti, E. Papageorgiou, J. Dervenoulas, T. Karmiris, S. Papageorgiou, N. Harhalakis, N. Xiros, et al.
A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4
Haematologica,
October 1, 2007;
92(10):
1343 - 1350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Prakash and S. H Swerdlow
Nodal aggressive B-cell lymphomas: a diagnostic approach
J. Clin. Pathol.,
October 1, 2007;
60(10):
1076 - 1085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Park, J. Lee, Y. H. Ko, A. Han, H. J. Jun, S. C. Lee, I. G. Hwang, Y. H. Park, J. S. Ahn, C. W. Jung, et al.
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
Blood,
August 1, 2007;
110(3):
972 - 978.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N Niitsu, M Okamoto, N Nakamura, H Nakamine, M Bessho, and M Hirano
Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma
Ann. Onc.,
July 1, 2007;
18(7):
1203 - 1208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood,
July 1, 2007;
110(1):
29 - 36.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-Y. Liu, C. Leboeuf, J.-Y. Shi, J.-M. Li, L. Wang, Y. Shen, J.-F. Garcia, Z.-X. Shen, Z. Chen, A. Janin, et al.
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma
Blood,
July 1, 2007;
110(1):
339 - 344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al.
Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma
Haematologica,
June 1, 2007;
92(6):
778 - 783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
Blood,
June 1, 2007;
109(11):
4930 - 4935.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Thieblemont and B. Coiffier
Lymphoma in Older Patients
J. Clin. Oncol.,
May 10, 2007;
25(14):
1916 - 1923.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
Ann. Onc.,
May 1, 2007;
18(5):
931 - 939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A Catherwood, D. Gonzalez, C. Patton, E. Dobbin, L. Venkatraman, and H D. Alexander
Improved clonality assessment in germinal centre/post-germinal centre non-Hodgkin's lymphomas with high rates of somatic hypermutation
J. Clin. Pathol.,
May 1, 2007;
60(5):
524 - 528.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Senff, J. J. Hoefnagel, P. M. Jansen, M. H. Vermeer, J. van Baarlen, W. A. Blokx, M. R. Canninga-van Dijk, M.-L. Geerts, K. M. Hebeda, P. M. Kluin, et al.
Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO-EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers
J. Clin. Oncol.,
April 20, 2007;
25(12):
1581 - 1587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. A. Deutsch, A. Aigelsreiter, P. B. Staber, A. Beham, W. Linkesch, C. Guelly, R. I. Brezinschek, M. Fruhwirth, W. Emberger, M. Buettner, et al.
MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation
Blood,
April 15, 2007;
109(8):
3500 - 3504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kunder, J. Calzada-Wack, G. Holzlwimmer, J. Muller, C. Kloss, W. Howat, J. Schmidt, H. Hofler, M. Warren, and L. Quintanilla-Martinez
A Comprehensive Antibody Panel for Immunohistochemical Analysis of Formalin-Fixed, Paraffin-Embedded Hematopoietic Neoplasms of Mice: Analysis of Mouse Specific and Human Antibodies Cross-Reactive with Murine Tissue
Toxicol Pathol,
April 1, 2007;
35(3):
366 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nakamura, T. Murase, and T. Kinoshita
Intravascular large B-cell lymphoma: the heterogeneous clinical manifestations of its classical and hemophagocytosis-related forms
Haematologica,
April 1, 2007;
92(4):
434 - 436.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gratzinger, S. Zhao, R. J. Marinelli, A. V. Kapp, R. J. Tibshirani, A. S. Hammer, S. Hamilton-Dutoit, and Y. Natkunam
Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes
Am. J. Pathol.,
April 1, 2007;
170(4):
1362 - 1369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Mohammad, A. S. Goustin, A. Aboukameel, B. Chen, S. Banerjee, G. Wang, Z. Nikolovska-Coleska, S. Wang, and A. Al-Katib
Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1
Clin. Cancer Res.,
April 1, 2007;
13(7):
2226 - 2235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Karube, Y. Guo, J. Suzumiya, Y. Sugita, Y. Nomura, K. Yamamoto, K. Shimizu, S. Yoshida, H. Komatani, M. Takeshita, et al.
CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features
Blood,
April 1, 2007;
109(7):
3076 - 3079.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al.
Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium
J. Clin. Oncol.,
March 1, 2007;
25(7):
805 - 812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Natkunam, S. Zhao, D. Y. Mason, J. Chen, B. Taidi, M. Jones, A. S. Hammer, S. Hamilton Dutoit, I. S. Lossos, and R. Levy
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas
Blood,
February 15, 2007;
109(4):
1636 - 1642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Natkunam, G. Vainer, J. Chen, S. Zhao, R. J. Marinelli, A. S. Hammer, S. Hamilton-Dutoit, E. Pikarsky, G. Amir, R. Levy, et al.
Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms
Haematologica,
February 1, 2007;
92(2):
176 - 183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. N. Naresh
MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes
Haematologica,
February 1, 2007;
92(2):
267 - 268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C van Galen, J. J F Muris, J. J Oudejans, W. Vos, C. P E Giroth, G. J Ossenkoppele, A. P Otte, F. M Raaphorst, and C. J L M Meijer
Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL
J. Clin. Pathol.,
February 1, 2007;
60(2):
167 - 172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Murase, M. Yamaguchi, R. Suzuki, M. Okamoto, Y. Sato, J.-i. Tamaru, M. Kojima, I. Miura, N. Mori, T. Yoshino, et al.
Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5
Blood,
January 15, 2007;
109(2):
478 - 485.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zimpfer, S. Schonberg, A. Lugli, C. Agostinelli, S. A Pileri, P. Went, and S. Dirnhofer
Construction and validation of a bone marrow tissue microarray
J. Clin. Pathol.,
January 1, 2007;
60(1):
57 - 61.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Dent, J. H. Herman, and J. E. Siegel
Laboratory hematology
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
444 - 465.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Schwaller, P. Schneider, P. Mhawech-Fauceglia, T. McKee, S. Myit, T. Matthes, J. Tschopp, O. Donze, F.-A. Le Gal, and B. Huard
Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness
Blood,
January 1, 2007;
109(1):
331 - 338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Cattoretti, R. Shaknovich, P. M. Smith, H.-M. Jack, V. V. Murty, and B. Alobeid
Stages of Germinal Center Transit Are Defined by B Cell Transcription Factor Coexpression and Relative Abundance
J. Immunol.,
November 15, 2006;
177(10):
6930 - 6939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Tierens, A. Warsame, H. Holte, and J. Delabie
Testicular Diffuse Large B-Cell Lymphoma of Activated B-Cel Subtype Is Frequently Associated with Clonally Related Non-Follicular Small B-Cell Lymphoma in the Bone Marrow.
Blood (ASH Annual Meeting Abstracts),
November 1, 2006;
108(11):
2042 - 2042.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-W. Chen, X.-T. Hu, A. C. Liang, W.-Y. Au, C.-C. So, M. L. Wong, L. Shen, Q. Tao, K.-M. Chu, Y.-L. Kwong, et al.
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma
Blood,
October 1, 2006;
108(7):
2373 - 2383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin
Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 1, 2006;
24(25):
4135 - 4142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Visco, L Arcaini, E Brusamolino, S Burcheri, A Ambrosetti, M Merli, E Bonoldi, M Chilosi, A Viglio, M Lazzarino, et al.
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy
Ann. Onc.,
September 1, 2006;
17(9):
1434 - 1440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Wallace, D. Shen, G. F. Reed, M. Miyanaga, M. Mochizuki, H. N. Sen, S. S. Dahr, R. R. Buggage, R. B. Nussenblatt, and C.-C. Chan
Detection of the bcl-2 t(14;18) Translocation and Proto-Oncogene Expression in Primary Intraocular Lymphoma.
Invest. Ophthalmol. Vis. Sci.,
July 1, 2006;
47(7):
2750 - 2756.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|